Dapivirine vaginal ring [25 mg vaginal delivery system] for HIV pre-exposure prophylaxis (PrEP) in adult women specifically as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches
Cycle 2 | DrugsHTA Council Recommendation (as of 12 November 2024)
The HTA Council positively recommends dapivirine vaginal ring [25 mg vaginal delivery system] for HIV pre-exposure prophylaxis (PrEP) in adult women specifically as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches for the inclusion in the PNF and thus the government financing of the said health technology.
Relevant Information
- Status: With Final HTA Council Recommendation with SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should dapivirine vaginal ring [25 mg vaginal delivery system] for HIV pre-exposure prophylaxis (PrEP) in adult women specifically as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches be funded by the government?
- Secretary of Health Decision: Approved as of 11 December 2024
Evidence and Relevant Documents